609 results on '"Stahl, Maximilian"'
Search Results
2. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
3. Mapping genotypes to chromatin accessibility profiles in single cells
4. RIOK2 transcriptionally regulates TRiC and dyskerin complexes to prevent telomere shortening
5. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML
6. E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial
7. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
8. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia
9. TP53-mutated acute myeloid leukemia: how can we improve outcomes?
10. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
11. When to use which molecular prognostic scoring system in the management of patients with MDS?
12. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
13. Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution
14. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
15. Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia
16. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes
17. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms
18. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
19. Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS
20. Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
21. Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells
22. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax
23. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.
24. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
25. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
26. Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis
27. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
28. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia
29. Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems?
30. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia
31. Is there a path forward for immunotherapy in patients with myelodysplastic syndromes?
32. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study
33. Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes
34. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
35. Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems?
36. FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years
37. Updates in classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium of MDS (icMDS)
38. AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML)
39. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study
40. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation
41. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
42. The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies
43. Development and Interrater Agreement of a Novel Classification System Combining Medical and Surgical Adverse Event Reporting
44. Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms
45. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age
46. Epidemiology and Pathogenesis of Myelodysplastic Syndrome
47. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis
48. Selecting initial treatment of acute myeloid leukaemia in older adults
49. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis
50. Is there a path forward for immunotherapy in patients with myelodysplastic syndromes?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.